Skip to main content
Erschienen in: Annals of Nuclear Medicine 1/2016

01.01.2016 | Original Article

Radioembolization with 90Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors

verfasst von: Cigdem Soydal, Ozlem Nuriye Kucuk, Sadik Bilgic, Erkan Ibis

Erschienen in: Annals of Nuclear Medicine | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Aim

To investigate the prognostic factors that predict overall survival after radioembolization in patients with cholangiocellular carcinoma.

Methods

The study comprised 16 patients who received radioembolization with Y90 resin microspheres for cholangiocarcinoma. The statistical relationships between overall survival after radioembolization and age, number, dimension and fluorodeoxyglucose (FDG) avidity of liver lesions, liver tumor load, presence of extrahepatic metastases, and radiological response were analyzed.

Results

Mean 1.7 ± 0.1 GBq90Y microspheres were administered to a total of 16 patients (mean age: 55.37 ± 17.7; 8 males, 8 females). Mean AST, ALT, and total bilirubin levels were calculated as 35 ± 15, 40 ± 37 IU/L, and 0.77 ± 0.37 mG/dL, respectively. In 6 patients, 1 liver lesion was determined, in 2 patients ≤5, and in 8 patients >5, with dimensions varying between 12 and 120 mm. The liver lesions of 13 patients were FDG avid (mean SUVmax: 7.4 ± 2.2). Extrahepatic metastases were demonstrated in 5 patients. Tumor load of 4, 8, and 4 patients was calculated as <25, 25–50, and >50 %, respectively. Five patients were responsive to treatment. During the follow-up period of 243 (range 98–839) days, 12 patients died. In Cox-regression analysis, FDG avidity (p = 0.02), the dimensions (p = 0.03) of the liver lesion, tumor load (p = 0.02), and radiological response (p = 0.01) were found to be statistically significant parameters predictive of overall survival after radioembolization (p = 0.006).

Conclusion

FDG avidity and the dimension of the largest liver lesion, tumor load, and radiological response are prognostic factors in patients receiving radioembolization for cholangiocellular carcinoma. Patients with lower tumor load, FDG-negative tumors, and smaller tumors seem to survive longer after radioembolization.
Literatur
1.
Zurück zum Zitat Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–25.PubMedCrossRef Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–25.PubMedCrossRef
2.
Zurück zum Zitat Altaee MY, Johnson PJ, Farrant JM, Williams R. Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer. 1991; 68:2051–5. Altaee MY, Johnson PJ, Farrant JM, Williams R. Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma. Cancer. 1991; 68:2051–5.
3.
Zurück zum Zitat Yi B, Zhang BH, Zhang YJ, Jiang XQ, Zhang BH, Yu WL, et al. Surgical procedure and prognosis of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2004;3:453–7.PubMed Yi B, Zhang BH, Zhang YJ, Jiang XQ, Zhang BH, Yu WL, et al. Surgical procedure and prognosis of hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 2004;3:453–7.PubMed
4.
Zurück zum Zitat Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–13.PubMedCrossRef Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–13.PubMedCrossRef
5.
Zurück zum Zitat Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–7.PubMedCrossRef Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–7.PubMedCrossRef
6.
Zurück zum Zitat Mazhar D, Stebbing J, Bower M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol. 2006;2:509–14.PubMedCrossRef Mazhar D, Stebbing J, Bower M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol. 2006;2:509–14.PubMedCrossRef
7.
Zurück zum Zitat Cianni R, Urigo C, Notarianni E, Saltarelli A, D’Agostini A, Iozzino M, et al. Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiol Med. 2010;115:619–33.PubMedCrossRef Cianni R, Urigo C, Notarianni E, Saltarelli A, D’Agostini A, Iozzino M, et al. Radioembolisation using yttrium 90 (Y-90) in patients affected by unresectable hepatic metastases. Radiol Med. 2010;115:619–33.PubMedCrossRef
8.
Zurück zum Zitat Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25:1067–73.PubMedCrossRef Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25:1067–73.PubMedCrossRef
9.
Zurück zum Zitat Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres—safety, efficacy, and survival. Radiology. 2008;247:507–15.PubMedCrossRef Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres—safety, efficacy, and survival. Radiology. 2008;247:507–15.PubMedCrossRef
10.
Zurück zum Zitat Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24:1227–34.PubMedPubMedCentralCrossRef Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24:1227–34.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113:2119–28.PubMedCrossRef Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113:2119–28.PubMedCrossRef
12.
Zurück zum Zitat Kao YH, Tan EH, Ng CE, Goh SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med. 2011;25:455–61.PubMedCrossRef Kao YH, Tan EH, Ng CE, Goh SW. Clinical implications of the body surface area method versus partition model dosimetry for yttrium-90 radioembolization using resin microspheres: a technical review. Ann Nucl Med. 2011;25:455–61.PubMedCrossRef
13.
Zurück zum Zitat Hoffmann RT, Paprottka PM, Schön A, Bamberg F, Haug A, Dürr EM, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35:105–16.PubMedCrossRef Hoffmann RT, Paprottka PM, Schön A, Bamberg F, Haug A, Dürr EM, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35:105–16.PubMedCrossRef
14.
Zurück zum Zitat Filippi L, Pelle G, Cianni R, Scopinaro F, Bagni O. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma. Nucl Med Biol. 2015;42:59–64.PubMedCrossRef Filippi L, Pelle G, Cianni R, Scopinaro F, Bagni O. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma. Nucl Med Biol. 2015;42:59–64.PubMedCrossRef
15.
Zurück zum Zitat Kucuk ON, Soydal C, Araz M, Bilgic S, Ibis E. Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT. Clin Nucl Med. 2013;38:283–9.CrossRef Kucuk ON, Soydal C, Araz M, Bilgic S, Ibis E. Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT. Clin Nucl Med. 2013;38:283–9.CrossRef
16.
Zurück zum Zitat Soydal C, Kucuk ON, Gecim EI, Bilgic S, Elhan AH. The prognosticvalue of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer. Nucl Med Commun. 2013;34:501–6.PubMedCrossRef Soydal C, Kucuk ON, Gecim EI, Bilgic S, Elhan AH. The prognosticvalue of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer. Nucl Med Commun. 2013;34:501–6.PubMedCrossRef
17.
Zurück zum Zitat Gulec SA, Suthar RR, Barot TC, Pennington K. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging. 2011;38:1289–95.PubMedCrossRef Gulec SA, Suthar RR, Barot TC, Pennington K. The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy. Eur J Nucl Med Mol Imaging. 2011;38:1289–95.PubMedCrossRef
Metadaten
Titel
Radioembolization with 90Y resin microspheres for intrahepatic cholangiocellular carcinoma: prognostic factors
verfasst von
Cigdem Soydal
Ozlem Nuriye Kucuk
Sadik Bilgic
Erkan Ibis
Publikationsdatum
01.01.2016
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 1/2016
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-015-1026-y

Weitere Artikel der Ausgabe 1/2016

Annals of Nuclear Medicine 1/2016 Zur Ausgabe